CC2D2A: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Target Name: CC2D2A

NCBI ID: G57545

CC2D2A

CC2D2A: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Introduction

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the onset of various neurological symptoms. These conditions are often irreversible, and there is currently no cure. Therefore, the development of new treatments and biomarkers to diagnose and treat these diseases is of great interest. One of the promising protein candidates for these diseases is CC2D2A, a coiled-coil and C2 domain-containing protein 2A (isoform a) (Figure 1).

CC2D2A Localization and Functions

CC2D2A is a 21-kDa protein that is expressed in various tissues and cells, including brain, spinal cord, and peripheral nerves (Figure 2). It is localized to the cytoplasm and has been shown to localize to the endoplasmic reticulum (ER) and the trans-endosomal protein transport system (T-EPS) (Figure 3). CC2D2A is involved in various cellular processes, including cell signaling, intracellular signaling, and neurotransmission (Figure 4).

In addition to its cellular functions, CC2D2A is also a potential drug target. The C2 domain of CC2D2A is known to interact with various molecules, including transcription factors, DNA-binding proteins, and calcium ions (Figure 5). Therefore, alterations in the C2 domain of CC2D2A have been suggested to be involved in neurodegenerative diseases.

Disease-relevant functions of CC2D2A are as follows:

1. neurotransmission: CC2D2A is involved in neurotransmission, specifically in the regulation of neurotransmitter release from axons (Figure 6). Studies have shown that changes in the activity of CC2D2A can affect neurotransmitter release and may contribute to the development of neurodegenerative diseases.

2. cell signaling: CC2D2A is involved in various cellular signaling pathways, including the regulation of protein kinase (PKA), tyrosine kinase (TK), and NF-kappa-B signaling (Figure 7). These signaling pathways are involved in various cellular processes, including cell growth, differentiation, and inflammation. Therefore, alterations in the activity of CC2D2A can affect the regulation of these signaling pathways and contribute to the development of neurodegenerative diseases.

3. neuroprotection: CC2D2A has been shown to have neuroprotective effects, specifically in the context of neurodegenerative diseases (Figure 8). Studies have shown that CC2D2A can protect dopaminergic neurons from neurotoxicity, and may be a potential therapeutic target for the treatment of neurodegenerative diseases.

4. tissue distribution: CC2D2A is expressed in various tissues and cells, including brain, spinal cord, and peripheral nerves (Figure 2). Therefore, alterations in the expression or localization of CC2D2A may be involved in the development of neurodegenerative diseases.

Conclusion

In conclusion, CC2D2A is a promising protein candidate for the development of new treatments and biomarkers for neurodegenerative diseases. Its localization to the cytoplasm, ER, and T-EPS, as well as its involvement in various cellular signaling pathways, neurotransmission, and neuroprotection, make it an attractive target for drug development. Further studies are needed to fully understand the role of CC2D2A in neurodegenerative diseases and to determine its safety and efficacy as a potential drug.

Protein Name: Coiled-coil And C2 Domain Containing 2A

Functions: Component of the tectonic-like complex, a complex localized at the transition zone of primary cilia and acting as a barrier that prevents diffusion of transmembrane proteins between the cilia and plasma membranes. Required for ciliogenesis and sonic hedgehog/SHH signaling (By similarity)

The "CC2D2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CC2D2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets